What is the recommended treatment regimen for lupus nephritis?

Treatment of Lupus Nephritis

For active Class III or IV lupus nephritis, initiate treatment with glucocorticoids combined with mycophenolate mofetil (MMF 2-3 g/day) or low-dose intravenous cyclophosphamide (500 mg every 2 weeks × 6 doses), followed by long-term maintenance with MMF or azathioprine and low-dose glucocorticoids (≤7.5 mg/day). 1

Initial (Induction) Treatment for Proliferative LN (Class III/IV)

The 2024 KDIGO guideline provides four equally recommended first-line options 1:

1. Mycophenolic acid analogs (MPAA) - Target dose MMF 2-3 g/day or equivalent MPA dose
2. Low-dose intravenous cyclophosphamide - 500 mg every 2 weeks for 6 doses
3. Belimumab + MPAA or cyclophosphamide - Triple therapy approach
4. MPAA + calcineurin inhibitor (CNI) - When eGFR >45 mL/min/1.73 m² and nephrotic-range proteinuria present

Glucocorticoid Dosing Strategy

The guideline emphasizes reduced glucocorticoid exposure to minimize toxicity 1:

• Methylprednisolone IV pulses: 250-500 mg/day for up to 3 days initially
• Oral prednisone: Start at 0.3-0.6 mg/kg/day (maximum 40-50 mg)
• Rapid taper: Reduce to 5-10 mg/day by week 12, then to <5 mg/day by week 24

This represents a significant shift from older high-dose regimens (0.8-1.0 mg/kg/day), reflecting evidence that lower doses achieve similar efficacy with fewer adverse effects 1, 2.

Choosing Between Initial Regimens

Clinical profiling guides therapy selection 1:

• MPAA-based regimen preferred for:

  • Patients at high risk of infertility
  • Those with prior cyclophosphamide exposure
  • Patients who can adhere to oral medication

• Cyclophosphamide preferred for:

  • Patients with adherence concerns (IV administration ensures compliance)
  • Severe disease with crescents or fibrinoid necrosis

• CNI-containing regimen (voclosporin or tacrolimus) preferred for:

  • Preserved kidney function (eGFR >45 mL/min/1.73 m²)
  • Nephrotic-range proteinuria (likely podocyte injury)
  • Patients intolerant to standard-dose MPAA

• Belimumab triple therapy preferred for:

  • Repeated kidney flares
  • High risk for progression to kidney failure
  • Severe chronic kidney disease

Maintenance Treatment

After achieving response (typically 3-6 months), transition to maintenance therapy 1, 2:

• First choice: MMF 1-2 g/day OR azathioprine 2 mg/kg/day
• Glucocorticoids: Taper to ≤5-7.5 mg/day prednisone
• Duration: Continue for 3-5 years minimum after achieving complete remission
• Hydroxychloroquine: Continue indefinitely (≤5 mg/kg/day, adjusted for GFR)

Choice between MMF and azathioprine 1:

• Use MMF if it was the induction agent
• Switch to azathioprine if pregnancy is planned (MMF is teratogenic)
• CNIs can be continued in pure Class V disease at lowest effective dose

Treatment Targets and Monitoring

The goal is complete renal response by 12 months 1, 2:

• Complete response: Proteinuria <0.5-0.7 g/g (PCR) with stable/improved kidney function
• Partial response: ≥50% reduction in proteinuria to <3 g/g with stable kidney function
• Timeline expectations:
  • 25% reduction in proteinuria by 3 months
  • 50% reduction by 6 months
  • Complete response by 12 months (may extend to 18-24 months for nephrotic-range baseline proteinuria)

Management of Inadequate Response

If response is unsatisfactory at 6-12 months 1:

1. Verify adherence and check drug levels (mycophenolic acid levels if on MPAA)
2. Consider repeat biopsy to assess for chronicity or alternative diagnosis (e.g., thrombotic microangiopathy)
3. Switch to alternative regimen from the four first-line options
4. Add rituximab for refractory disease (1000 mg on days 0 and 14) 2
5. Consider enrollment in clinical trials for novel biologics (obinutuzumab, anifrolumab)

Pure Membranous LN (Class V)

For Class V with nephrotic-range proteinuria or proteinuria >1 g/24h despite RAAS blockade 1:

• Preferred: MMF 2-3 g/day + glucocorticoids (methylprednisolone pulses followed by prednisone 20 mg/day, taper to <5 mg/day by 3 months)
• Alternatives:
  • CNI monotherapy (tacrolimus or voclosporin) for nephrotic-range proteinuria
  • CNI + MMF combination for enhanced efficacy
  • Low-dose cyclophosphamide

Voclosporin achieved median time to proteinuria <0.5 g/g of 3.6 months in Class V disease 1.

Critical Adjunctive Therapies

All patients require 1:

• Hydroxychloroquine: ≤5 mg/kg/day (improves outcomes, reduces flares)
• RAAS blockade: ACE inhibitor or ARB for proteinuria >0.5 g/g or hypertension
• SGLT2 inhibitors: For renoprotection in CKD
• Anticoagulation: Consider if antiphospholipid antibodies present or nephrotic syndrome
• Bone protection: Calcium/vitamin D supplementation, bisphosphonates with chronic glucocorticoid use
• Infection prophylaxis: PJP prophylaxis during intensive immunosuppression
• Contraception counseling: Avoid unplanned pregnancy (MMF, cyclophosphamide are teratogenic)

Common Pitfalls to Avoid

1. Premature treatment switching: Allow adequate time for response, especially with baseline nephrotic-range proteinuria (up to 18-24 months)
2. Excessive glucocorticoid exposure: Use reduced-dose regimens; cumulative toxicity increases morbidity
3. Cyclophosphamide overuse: Limit lifetime exposure to <36 g to reduce malignancy and infertility risk 1
4. Stopping hydroxychloroquine: Continue indefinitely unless contraindicated
5. Inadequate maintenance duration: Continue for minimum 3-5 years after complete remission
6. Ignoring cardiovascular risk: LN patients have elevated CV disease burden requiring aggressive risk reduction 3

Emerging Evidence

The 2024 KDIGO guideline represents the most current evidence, incorporating recent trials showing benefit of triple therapy with belimumab and CNI-based regimens 1. The approval of obinutuzumab (anti-CD20 antibody) and ongoing CAR T-cell therapy trials are transforming the landscape 4, though these are reserved for refractory cases currently. The trend is toward earlier combination therapy targeting multiple immune pathways while minimizing glucocorticoid exposure 5.